This profile describes access and programme structure. Inclusion is not an endorsement, regulatory finding, or clinical recommendation. Prescription decisions belong to a qualified prescriber.
At a glance
Pricing, medicine, location, care, fulfilment, funding, and policy claims are separated below.
An open check means the public sources were not specific enough—not that the service failed the check.
Resumen en español
Hims para usuarios hispanohablantes
Esta sección ofrece una orientación breve en español sobre el perfil estadounidense. La investigación completa de precios, acceso, farmacia y seguimiento permanece arriba mientras ampliamos la revisión editorial en español.
No encontramos una fuente primaria suficientemente específica para afirmar que una cita clínica esté disponible en español. Confirma el idioma y cualquier servicio de interpretación antes de pagar.
- si la cita concreta será en español;
- el coste mensual ordinario y qué incluye;
- la licencia estatal del profesional;
- el medicamento, la farmacia y el coste por separado.
Esta traducción editorial no demuestra que el proveedor ofrezca atención clínica en español y no sustituye una valoración médica.
Comparar proveedores para hispanohablantes en EE. UU. →How the program is structured
A men-focused membership with a current menu of FDA-approved oral and injectable medications, 24/7 provider messaging, tracking, smart-scale tools, and dose support. The care fee and medication are separate.
GLP.directory checked the cited public sources on Sep 13, 2026. We reviewed published access, cost, care, fulfilment, funding, cancellation, monitoring, and switching details; we have not audited individual clinical encounters, prescriptions, pharmacy operations, or outcomes.
Availability can change by state, clinician, medical history, product, pharmacy, inventory, and insurance plan. “Not publicly confirmed” means we did not find a sufficiently specific answer in the cited public material. Confirm the current patient-specific answer before paying or changing care.
Service configuration
These structured fields power the directory filters. They describe the reviewed public route and should be reconfirmed for the selected plan.
- Provider type
- Telehealth program
- Medicine context
- Semaglutide (Wegovy; Ozempic/Rybelsus for type 2 diabetes) · Tirzepatide (Zepbound; Mounjaro for type 2 diabetes)
- Formats reviewed
- Injection · Oral medicine
- Funding routes
- Private pay
- Service features
- Clinician support · Switching pathway · Home delivery
- Access check
- Confirm current state access
- Evidence status
- Primary sources reviewed
- Research depth
- 2 cited sources · 4 medicine rows · 4 open checks
Recurring cost breakdown
- $39 introductory month; $149/month ongoing membership.
- Medication-only prices displayed at review ranged from $149 for selected pills to $1,899 for certain injectable brand routes.
- Membership includes provider messaging, tracking, smart-scale features, and clinical support.
- Labs, if required, are not described as a universal medication-price inclusion.
- Medicine + dose
- Membership or consultation
- Delivery + supplies
- Labs + follow-up
- Renewal after offers
Medication and formulation matrix
| Medication | Form | Regulatory / program path | Published price view |
|---|---|---|---|
| Wegovy | Daily pill / weekly pen | FDA-approved brand | $149 pill / $199 pen medication-only at review |
| Zepbound | Vial, KwikPen or pen | FDA-approved brand | From $299; some routes displayed up to $1,899 |
| Foundayo / Ozempic pill | Daily pill | FDA-approved brands; indication differs | $149 medication-only at review |
| Ozempic / Mounjaro | Weekly injection | FDA-approved for type 2 diabetes | $199 to $1,899 depending route at review |
Important: “Compounded” means the product is not FDA approved. A brand approved for one condition is not automatically approved for another. The treating clinician determines whether any prescription is appropriate.
State-by-state availability
- The program states that treatment is not available in every state.
- Availability must be checked for the specific medication and patient location.
Clinician access and follow-up cadence
- Online intake and licensed-provider review precede prescribing.
- 24/7 provider messaging, side-effect support, and dose adjustment are advertised.
- The public page does not promise a fixed schedule of live video visits.
Pharmacy and fulfillment
- Fulfillment varies by medication and may use home delivery or a manufacturer/retail channel.
- Confirm the named pharmacy, shipment interval, and replacement policy for the selected route.
Insurance and prior authorization
- The displayed program is primarily transparent cash access; insurance is not required.
- Any reimbursement or savings-program eligibility is product-specific and should not be assumed.
Cancellation, refund, and commitment
- Membership renews until canceled.
- Review the cutoff for the next medication order separately from membership cancellation; dispensed prescriptions generally cannot be returned.
Labs, monitoring, and dose management
- No universal included lab bundle was published.
- The provider can require monitoring based on history, medication, and reported effects.
Maintenance and switching
- The intake supports disclosure of current GLP-1 use and may support continuation.
- Identical medication, dose, and timing remain subject to provider approval and inventory.
Program snapshot
Membership plus medication
Profiled support: Ongoing clinician access, Simplified intake and fulfillment.
Cash pay
Hims states that insurance is not required; the reviewed route is direct cash pay.
Verify before purchase
The product-specific dispensing route is separate from the membership. Review the treatment disclosure before purchase.
What the advertised program may include
- Online intake and clinician review
- Medication when prescribed
- Digital care access
- Shipping for eligible plans
Useful comparison signals
Based on the provider’s published program structure, this profile is tagged for the following searches. These are filters, not endorsements or clinical recommendations.
- Starting care and comparing first-provider requirements
- Switching providers or continuing an established treatment
- Comparing lower-cost access routes and recurring totals
- Ongoing clinician access
- Simplified intake and fulfillment
Open evidence gaps
These are material details we could not confirm precisely enough from the cited public pages. They are the highest-priority questions to resolve directly.
- State-by-product table
- Named dispensing pharmacy by route
- Fixed live-visit cadence
- Universal lab cost
Questions to ask before paying
- What is the ordinary recurring total after any introductory period?
- Does that total include clinician care, medication, supplies, labs, and shipping?
- Which clinician group and dispensing pharmacy will be responsible for my care?
- What happens to billing if I am not prescribed the advertised treatment?
- What records and timing do you require if I am switching from another provider?
Source ledger
Every entry below is a provider-controlled or official public source. A source link documents what was published; it does not independently validate performance, regulatory compliance, safety, or outcomes.
Current membership, medication menu, pricing, support and state caveats
Subscription, renewal and service terms